Tag: MaaT033
MaaT Pharma presents positive results for MaaT013, its most advanced drug candidate, at ASH 2023 and details the ongoing Phase 2b trial evaluating MaaT033 – 11/12/2023 at 07:38
MaaT Pharma presents positive results for MaaT013, its most advanced drug candidate, at ASH 2023 and details the ongoing Phase 2b trial evaluating MaaT033 • Positive efficacy results from 111…
MaaT Pharma, leader in the development of drugs based on intestinal microbiota in oncology, receives funding from the State for the clinical development of MaaT033 as part of the France 2030 Plan – 11/30/2023 at 6:05 p.m.
MaaT Pharma, leader in the development of drugs based on intestinal microbiota in oncology, receives funding from the State for the clinical development of MaaT033 as part of the France…
MaaT Pharma: treatment of a first patient in the randomized Phase 2b clinical trial evaluating MaaT033 in patients receiving allo-HSCT
By Claude Leguilloux Published on 06/11/2023 at 08:01 a.m. Photo credit © Boursier.com (Boursier.com) — MaaT Pharmaa late-stage…
MaaT Pharma: presentation of two posters for MaaT013 and MaaT033 at the next ASH conference
By Hector Chaunu Published on 02/11/2023 at 6:22 p.m. Photo credit © ChaunuPictures (Boursier.com) — MaaT Pharmaa late-stage…
MaaT Pharma announces the presentation of two posters for MaaT013 and MaaT033 at the next ASH conference – 02/11/2023 at 6:12 p.m.
MaaT Pharma announces the presentation of two posters for MaaT013 and MaaT033 at the next ASH conference • The first poster will present the results of 111 patients with acute…
Maat Pharma: MaaT033 declared an orphan drug by the EMA – 09/07/2023 at 2:26 p.m.
(AOF) – Maat Pharma announces that its drug MaaT033 (capsule), currently developed as an adjuvant treatment to improve the overall survival of patients who have received a hematopoietic stem cell…
MaaT Pharma to Present Clinical Data for MaaT013 and MaaT033 at EBMT’s 49th Annual Meeting
By Hector Chaunu Published on 04/11/2023 at 22:04 Photo credit © ChaunuPictures (Boursier.com) — MaaT Pharmaa French late-stage…
MaaT Pharma to Present Clinical Data for MaaT013 and MaaT033 at EBMT’s 49th Annual Meeting – 2023-04-11 18:15
MaaT Pharma to Present Clinical Data for MaaT013 and MaaT033 at EBMT’s 49th Annual Meeting • The data was previously shared at the American Society of Hematology (ASH) Annual Meeting…
MaaT Pharma receives two regulatory authorizations for its two clinical trial applications in Europe to evaluate MaaT033 in two therapeutic indications – 03/27/2023 at 18:15
MaaT Pharma receives two regulatory approvals for its two clinical trial applications in Europe to evaluate MaaT033 in two therapeutic indications: • the Company received French and German regulatory authorizations…
MaaT Pharma Presents Promising Full Results for MaaT033 from Phase Ib Study at ASH 64th Annual Meeting – 12/11/2022 at 16:21
On the occasion of the 64th annual meeting of the American Society of Hematology (ASH), the world’s largest hematology meeting currently taking place in the United States, MaaT Pharma today…
MaaT Pharma confirms the positive results of the CIMON Phase 1b study evaluating MaaT033 in patients with blood cancer – 06/02/2022 at 18:11
Lyon, France, June 2, 2022 – 6:00 p.m. CEST – MaaT Pharma (EURONEXT: MAAT – the “Company”), a French clinical-stage biotechnology company pioneering the development of Microbiome Ecosystem TherapiesTM (MET)…
Maat Pharma, its MaaT033 treatment induces good colonization of the microbiota
The title of bioteh is however down on the stock market. The company hopes to quickly move from phase 1b to phase 2/3. Maat Pharma, its MaaT033 treatment induces good…